The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S42-S47 , November 2004

PROSTATE SPECIFIC ANTIGEN DOUBLING TIME AS A SURROGATE END POINT FOR PROSTATE CANCER SPECIFIC MORTALITY FOLLOWING RADICAL PROSTATECTOMY OR RADIATION THERAPY

  • ANTHONY V. D'AMICO

      Affiliations

    • Corresponding Author InformationCorrespondence: Department of Radiation Oncology, Brigham and Women's Hospital, 75 Francis St., L-2 Level, Boston, Massachusetts 02215 (telephone: 617-732-7936; FAX: 617-975-0912)
    • ,
  • JUDD MOUL

      Affiliations

    • Financial interest and/or other relationship with AstraZeneca, Sanofi and Theralogix
    • ,
  • PETER R. CARROLL

      Affiliations

    • Financial interest and/or other relationship with TAP Pharmaceuticals
    • ,
  • LEON SUN
    • ,
  • DEBORAH LUBECK
    • ,
  • MING-HUI CHEN

REFERENCES 

  1. Moul JW . Prostate specific antigen only progression of prostate cancer . J Urol . 2000;163:1632
  2. Grossfeld GD , Stier DM , Flanders SC , Henning JM , Schonfeld W , Warolin K , et al.   Use of second treatment following definitive local therapy for prostate cancer. Data from the CaPSURE Database . J Urol . 1998;160:1398
  3. D'Amico AV . Predicting prostate-specific antigen recurrence established: now, who will survive? . J Clin Oncol . 2002;20:3188
  4. Pound CR , Partin AW , Eisenberger MA , Chan DW , Pearson JD , Walsh PC . Natural history of progression after PSA elevation following radical prostatectomy . JAMA . 1999;281:1591
  5. Patel A , Dorey F , Franklin J , De Kernion JB . Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen . J Urol . 1997;158:1441
  6. Roberts SG , Blute ML , Bergstralh EJ , Slezak JM , Zincke H . PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer . Mayo Clin Proc . 2001;76:576
  7. Lee WR , Hanks GE , Hanlon A . Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations . J Clin Oncol . 1997;15:230
  8. Sartor CI , Strawderman MH , Lin XH , Kish KE , McLaughlin PW , Sandler HM . Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy . Int J Radiat Oncol Biol Phys . 1997;38:941
  9. D'Amico AV , Cote K , Loffredo M , Renshaw AA , Schultz D . Determinants of prostate cancer specific survival following radiation therapy for patients with clinically localized prostate cancer . J Clin Oncol . 2002;20:4567
  10. Sandler HM , Dunn RL , McLaughlin PW , Hayman JA , Sullivan MA , Taylor JM . Overall survival after prostate-specific-antigen detected recurrence following conformal radiation therapy . Int J Radiat Oncol Biol Phys . 2000;48:629
  11. Lubeck DP , Litwin MS , Henning JM , Stier DM , Mazonson P , Fisk R , et al.   The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel: Cancer of the Prostate Strategic Urologic Research Endeavor . Urology . 1996;48:773
  12. Sun L , Gancarczyk K , Paquette EL , McLeod DG , Kane C , Kusuda L , et al.   Introduction to the Department of Defense Center for Prostate Disease Research Multicenter National Prostate Cancer Database, and analysis of changes in the PSA-era . Urol Oncol . 2001;6:203
  13. D'Amico AV , Moul J , Carroll P , Sun L , Lubeck D , Chen M . Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy . J Natl Ca Inst . 2003;95:1376
  14. Soloway MS , Pareek K , Sharifi R , Wajsman Z , McLeod D , Wood DP , et al.   Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results . J Urol . 2002;167:112
  15. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus panel . Int J Radiat Oncol Biol Phys . 1997;37:1035
  16. Prentice RL . Surrogate endpoints in clinical trials: definition and operational criteria . Stat Med . 1989;8:431
  17. Simultaneous inferences and other topic in regression analysis-1 . In:  Neter J ,  Wasserman W ,  Kutner MH editor. Applied Linear Regression Models . Homewood, Illinois: Richard D. Irwin, Inc.; 1983;p. 150–153
  18. D'Amico AV , Moul J , Carroll P , Sun L , Lubeck D , Chen M . Cancer specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era . J Clin Oncol . 2003;21:2163
  19. Gaynor JJ , Feur EJ , Tan CC , Wu DH , Little CR , Straus DJ , et al.   On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data . J Am Stat Assoc . 1993;88:400
  20. Kaplan EL , Meier P . Non-parametric estimation from incomplete observations . J Am Stat Assoc . 1958;53:457
  21. D'Amico AV . Combined-modality staging for localized adenocarcinoma of the prostate . Oncology . 2001;15:1049
  22. Kattan MW , Easthan JA , Stapleton AMF , Wheeler TM , Scardino PT . A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer . JNCI . 1998;90:766
  23. Kattan MW , Wheeler TM , Scardino PT . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer . J Clin Oncol . 1999;17:1499
  24. Moul JW , Connelly RR , Lubeck DP , Bauer JJ , Sun L , Flanders SC , et al.   Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases . J Urol . 2001;166:1322
  25. D'Amico AV , Whittington R , Malkowicz SB , Wu YH , Chen MH , Hurwitz M , et al.   Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant therapy trials . J Clin Oncol . 2000;18:3240

 Supported by the Department of Defense Center for Prostate Disease Research funded by the United States Army Medical Research and Material Command, Fort Dietrick, Maryland and the Prostate Cancer Foundation, formally known as CaPCURE.The opinions and assertions herein are the private views of the authors and are not to be construed as reflecting the views of the United States Army or Department of Defense.

PII: S0022-5347(05)61307-9

doi: 10.1097/01.ju.0000141845.99899.12

The Journal of Urology
Volume 172, Issue 5, Supplement , Pages S42-S47 , November 2004

Article Tools

* Image Usage & Resolution